Keywords: cytokine; COVID-19; clinical value; course of disease;
Q: What’s already known about this topic?
A: Symptoms of COVID-19 patients, infection pathways of SARS-CoV-2, and the COVID-19 patients have higher cytokines.
Q: What does this article add?
A: What kinds of cytokines of COVID-19 patients were increased, whether they serve as diagnostic biomarkers of COVID-19 and offer prognostic insight upon initial presentation to help guide treatment, their relationship with age, gender,antibody concentration and course of disease were also discussed.
Coronavirus disease 19 (COVID-19) was first discovered in Wuhan, Hubei in December 2019 [1], then the epidemic spread throughout China and other countries and regions abroad[2]. The virus has high infectivity and caused serious damage to the global economy and the health of people all over the world. The main methods for diagnosing novel coronavirus (SARS-CoV-2) were nucleic acid detection and serological antibody detection [3]. According to diagnosis and treatment plan of COVID-19 (trial version 7) issued by the office of the Chinese health and Health Commission and the office of the State Administration of traditional Chinese medicine, inflammatory factors are often increased in severe and critical patients[4]. The immune cells can secrete cytokines (CKs) such as interleukin (IL), colony-stimulating factor (CSF), chemokine, interferon (IFN), tumor necrosis factor (TNF) and growth factor (GF) which can induce the activation, proliferation or migration of target cells by binding to specific receptors on a variety of cells when the body was immune to exogenous substances [5]. Our study aims to detect the expression level of IL-10, IL-1β, IL-6, monocyte chemoattractant protein-1 (MCP-1), TNF-α, interferon-inducible protein -10 (IP-10) and IL-4 in the blood of in COVID-19 patients, other diseases patients and healthy people, and discuss its diagnostic value for diagnosis of COVID-19.
Materials and methods
1.1 Materials